Article

First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma

2024-02-07

Abstract excerpt

<title>Abstract</title> <p>Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 is our first-in-human experience in patients with relapsed and refractory neuroblastoma using chimeric antigen receptor (CAR) T cells targeting L1-CAM, an adhesion molecule that is overexpressed in neuroblastoma with limited normal tissue expression. This trial evaluated three different CAR constructs:...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5fdbc21c-4596-5ddc-b61d-55768fa0cc33
DOI: 10.21203/rs.3.rs-3859120/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaDOI 10.21203/rs.3.rs-3859120/v1Read

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors: A Systematic Review and Meta-AnalysisSemantic proximity Read

GD2-specific Chimeric Antigen Receptor-modified T Cells for the treatment of Refractory and/or Recurrent Neuroblastoma in Pediatric PatientsSemantic proximity Read

State of the Art in Immunotherapy of NeuroblastomaSemantic proximity Read

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacySemantic proximity Read

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion TrialSemantic proximity Read

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read

Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for NeuroblastomaSemantic proximity Read

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read

Genetic engineering of cytolytic T lymphocytes for adoptive T‐cell therapy of neuroblastomaSemantic proximity Read

Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cellsSemantic proximity Read

Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patientsSemantic proximity Read